Literature DB >> 12086164

Bone mineral density in women with systemic lupus erythematosus.

H P Bhattoa1, P Bettembuk, A Balogh, G Szegedi, E Kiss.   

Abstract

The aim of this cross-sectional study was to determine the prevalence of reduced bone mineral density (BMD) in a group of female SLE patients and to identify factors predictive of reduced BMD. Femoral neck (FN) and lumbar spine (LS) dual-energy X-ray absorptiometry results were evaluated in 79 pre- and postmenopausal women with SLE aged (mean, range) 49 (22-73) years). Variables evaluated were disease duration, SLEDAI, current and cumulative corticosteroid dose, Steinbrocker's functional classification, use of immunosuppressive agents, and history of fracture due to minor trauma. A T-score of < or = 1.0 was found in 61.9% at the LS and 48.3% at the FN, and 18 (23.7%) patients belonged to the category of osteoporosis at LS, compared to only three (5.4%) patients at FN. A statistical difference (P = 0.014) was found when comparing LS BMD in pre- and postmenopausal patients. LS BMD had a significant correlation with daily and cumulative steroid dose (P = 0.016 and 0.031, respectively). There was a significant difference in LS BMD between the daily steroid dose group receiving < or = 7.5 and those receiving > 7.5 mg/day (P = 0.008), and also in FN BMD comparing groups on 0 and > 7.5 mg/day (P = 0.022). There was significant difference in LS and FN BMD between patients in Steinbrocker classes I and III (P = 0.016 and 0.005, respectively). No significant correlation was found in either subgroup between BMD and other studied parameters. We concluded that the prevalence of reduced bone mass at LS is pronounced among postmenopausal women with SLE, in those with a high Steinbrocker functional classification and those on a high daily steroid dose. Therefore, these patients should be considered as a high-risk group deserving regular spinal BMD scans and therapy in time to prevent vertebral fractures.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12086164     DOI: 10.1007/s10067-002-8272-9

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  10 in total

1.  Six-year follow-up study of bone mineral density in patients with systemic lupus erythematosus.

Authors:  J Jacobs; L-A Korswagen; A M Schilder; L H van Tuyl; B A C Dijkmans; W F Lems; A E Voskuyl; I E M Bultink
Journal:  Osteoporos Int       Date:  2012-10-03       Impact factor: 4.507

2.  Prevalence of and risk factors for low bone mineral density in Japanese female patients with systemic lupus erythematosus.

Authors:  Makio Furukawa; Chikako Kiyohara; Hiroshi Tsukamoto; Hiroki Mitoma; Yasutaka Kimoto; Ayumi Uchino; Misato Nakagawa; Kensuke Oryoji; Terufumi Shimoda; Koichi Akashi; Mine Harada; Takahiko Horiuchi
Journal:  Rheumatol Int       Date:  2009-12-18       Impact factor: 2.631

Review 3.  Bone health in systemic lupus erythematosus.

Authors:  Pantelis Panopalis; Jinoos Yazdany
Journal:  Curr Rheumatol Rep       Date:  2009-07       Impact factor: 4.592

4.  Risks factors for low bone mineral density in pre-menopausal Mexican women with systemic lupus erythematosus.

Authors:  Claudia Mendoza-Pinto; Mario García-Carrasco; Hilda Sandoval-Cruz; Ricardo O Escárcega; Mario Jiménez-Hernández; Ivet Etchegaray-Morales; Elena Soto-Vega; Margarita Muñoz-Guarneros; Aurelio López-Colombo; Margarita Delezé-Hinojosa; Ricard Cervera
Journal:  Clin Rheumatol       Date:  2008-08-01       Impact factor: 2.980

5.  Ibandronate increases cortical bone density in patients with systemic lupus erythematosus on long-term glucocorticoid.

Authors:  Edmund K Li; Tracy Y Zhu; Vivian Y Hung; Anthony W Kwok; Vivian W Lee; Kenneth K Lee; James F Griffith; Martin Li; Kong Chiu Wong; Ping Chung Leung; Ling Qin; Lai Shan Tam
Journal:  Arthritis Res Ther       Date:  2010-10-22       Impact factor: 5.156

Review 6.  Glucocorticoid-induced osteoporosis in rheumatic diseases.

Authors:  Rosa Maria Rodrigues Pereira; Jozélio Freire de Carvalho; Ernesto Canalis
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

7.  The effect of 1-year transdermal estrogen replacement therapy on bone mineral density and biochemical markers of bone turnover in osteopenic postmenopausal systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial.

Authors:  H P Bhattoa; P Bettembuk; A Balogh; G Szegedi; E Kiss
Journal:  Osteoporos Int       Date:  2003-12-16       Impact factor: 4.507

8.  Relationship between serum total cholesterol level and serum biochemical bone turnover markers in healthy pre- and postmenopausal women.

Authors:  Tae-Dong Jeong; Woochang Lee; Sung-Eun Choi; Jae Seung Kim; Hong-Kyu Kim; Sung Jin Bae; Sail Chun; Won-Ki Min
Journal:  Biomed Res Int       Date:  2014-05-15       Impact factor: 3.411

Review 9.  Bone mineral density and vertebral fractures in patients with systemic lupus erythematosus: A systematic review and meta-regression.

Authors:  Claudia Mendoza-Pinto; Adriana Rojas-Villarraga; Nicolás Molano-González; Erick A Jiménez-Herrera; María de la Luz León-Vázquez; Álvaro Montiel-Jarquín; Mario García-Carrasco; Ricard Cervera
Journal:  PLoS One       Date:  2018-06-13       Impact factor: 3.240

10.  Osteoporosis in Systemic Lupus Erythematosus - Correlations with Disease Activity and Organ Damage.

Authors:  A Barbulescu; F A Vreju; C Criveanu; A Rosu; P Ciurea
Journal:  Curr Health Sci J       Date:  2015-04-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.